Julie Rosenthal, MD, MS, discusses signs and symptoms of age-related macular degeneration as well as methods of treatment. Rosenthal: Some people don't have any symptoms at all when the disease is ...

Age-related macular degeneration (AMD) is a leading cause of vision loss among people aged 50 and older. While treatments for the wet form of AMD have shown promise, the dry form, which accounts for ...

Read this issue’s cover story titled “Specialists navigate changing, challenging landscape of geographic atrophy management.” More knowledge about the diagnosis and manageme ...

AMD primarily affects central vision, complicating activities like reading and driving, but does not cause complete blindness. Wet AMD involves abnormal blood vessel growth, while dry AMD progresses ...

Age-related macular degeneration (AMD) is the leading cause of visual impairment in people over age 50 years. It affects the macula, the central part of the retina responsible for sharp vision. There ...

ORLANDO ‑- Cataract surgery was linked to an increased risk of conversion from dry to neovascular (wet) age-related macular degeneration (AMD) in a large retrospective cohort study, although the ...

Even in an era of remarkable therapeutics for neovascular age-related macular degeneration, there remains a lack of therapies to improve vision in dry AMD. Many patients continue to live with central ...

At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...

Many of us are painfully aware of our body's increasing number of shortcomings as we get older. Sagging skin, hearing loss, receding hairlines and tending to use the bathroom more frequently than we ...

Manassas, Virginia--(Newsfile Corp. - July 9, 2025) - Notal Vision, a digital healthcare provider advancing remote patient monitoring in ophthalmology, announced the publication of pivotal study data ...

PARIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, ...